Differentiation of human embryonic stem cells

• US 10,076,544 B2
• Filed: 07/19/2010
• Issued: 09/18/2018
• Est. Priority Date: 07/20/2009
• Status: Active Grant

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Xu, Jean
• Primary Examiner(s): Ton, Thaian N
• Assistant Examiner(s): Montanari, David A
• Application Number:
  US12/838,998
• Publication Number:
  US 20110014163A1
• Time in Patent Office: 2,983 Days
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.

Claims

1. A method for lowering blood glucose levels in a mammal, comprising the steps of:

(a) differentiating a population of definitive endoderm cells into a population of pancreatic endoderm cells,

(b) differentiating the pancreatic endoderm cells of step (a) in a DMEM-high glucose medium comprising an exogenous retinoid to obtain a population of pancreatic endocrine precursor cells expressing insulin, NKX6.1 and PDX1, but not expressing CDX2; and

(c) transplanting the population of pancreatic endocrine precursor cells of step (b) into the liver, natural pancreas, renal subcapsular space, omentum, peritoneum, subserosal space, intestine, or a subcutaneous pocket of the mammal, wherein the pancreatic endocrine precursor cells express insulin, lower the blood glucose levels in the mammal and are protected from host immune response when transplanted.

2. The method of claim 1, wherein step (b) further comprises:

(i) culturing pancreatic endoderm cells in DMEM high glucose medium supplemented with FGF7, retinoic acid, a BMP inhibitor and a sonic hedgehog signaling inhibitor; and

(ii) culturing the cells of step (i) in DMEM high glucose medium supplemented with a BMP inhibitor and a TGF-β

receptor I kinase inhibitor.

3. The method of claim 2, wherein the BMP inhibitor is noggin.

4. The method of claim 2, wherein the sonic hedgehog signaling inhibitor is cyclopamine-KAAD.

5. The method of claim 2, wherein the TGF-β

receptor I kinase inhibitor is Alk5 inhibitor II.

6. The method of claim 1, wherein the pancreatic endocrine precursor cells are transplanted into the renal subcapsular space, omentum, peritoneum, or subserosal space.

7. The method of claim 1, wherein the insulin expressing cells are in a biocompatible degradable polymeric support, a porous non-degradable device or encapsulated when transplanted.

8. The method of claim 7, wherein the insulin expressing cells are encapsulated.

9. The method of claim 8, wherein the encapsulated cells are transplanted subcutaneously.

10. The method of claim 1, wherein the DMEM-high glucose medium in step (b) further comprises a TGF-β

receptor I kinase inhibitor and the differentiation is carried out for about eight days.

18. The method of claim 1 or claim 11, wherein the DMEM-high glucose medium comprises a TGF-β

receptor I kinase inhibitor.

19. The method of claim 18, wherein the TGF-β

receptor I kinase inhibitor is Alk 5 inhibitor II.

38. The method of claim 18, wherein the TGF-β

receptor I kinase inhibitor is Alk 5 inhibitor II.

11. A method for lowering blood glucose levels in a mammal, comprising the steps of:

(a) obtaining a population of definitive endoderm cells,

(b) differentiating a population of definitive endoderm cells into a population of pancreatic endoderm cells,

(c) differentiating the pancreatic endoderm cells of step (b) in a DMEM-high glucose medium comprising an exogenous retinoid to obtain a population of pancreatic endocrine precursor cells expressing NKX6.1 and PDX1, but not expressing CDX2,

(d) differentiating the pancreatic endocrine precursor cells of step (c) in a DMEM-high glucose medium to obtain a population of cells expressing insulin; and

(e) transplanting the population of insulin expressing cells of step (d) into the liver, natural pancreas, renal subcapsular space, omentum, peritoneum, subserosal space, intestine, or a subcutaneous pocket of the mammal, wherein the pancreatic endocrine precursor cells express insulin, lower the blood glucose levels in the mammal and are protected from host immune response when transplanted.

12. The method of claim 11, wherein the insulin expressing cells are transplanted into the renal subcapsular space, omentum, peritoneum, or subserosal space.

13. The method of claim 11, wherein the insulin expressing cells are in a biocompatible degradable polymeric support, a porous non-degradable device or encapsulated when transplanted.

14. The method of claim 13, wherein the cells are encapsulated.

15. The method of claim 14, wherein the encapsulated cells are transplanted subcutaneously.

16. The method of claim 11, wherein the medium of step (d) further comprises betacellulin and a TGF-β

receptor I kinase inhibitor.

17. The method of claim 16, wherein the TGF-β

receptor I kinase inhibitor is Alk 5 inhibitor II.

20. A method for lowering blood glucose levels in a mammal, comprising the steps of:

(a) differentiating a population of definitive endoderm cells into a population of pancreatic endoderm cells,

(b) differentiating the pancreatic endoderm cells of step (b) in a DMEM-high glucose medium comprising an exogenous retinoid to obtain a population of pancreatic endocrine precursor cells expressing insulin, NKX6.1 and PDX1, but not expressing CDX2, wherein the pancreatic endocrine precursor cells have increased expression of NKX6.1, PFT1a and NGN-3 as compared to pancreatic endocrine cells obtained from pancreatic endoderm cells differentiated in DMEM-low glucose, CMRL and DM-F12,

(c) transplanting the population of pancreatic endocrine precursor cells of step (c) into the liver, natural pancreas, renal subcapsular space, omentum, peritoneum, subserosal space, intestine, or a subcutaneous pocket of the mammal, wherein the pancreatic endocrine precursor cells express insulin, lower the blood glucose levels in the mammal and are protected from host immune response when transplanted.

21. The method of claim 20, wherein step (b) further comprises:

(i) culturing pancreatic endoderm cells in DMEM high glucose medium supplemented with FGF7, retinoic acid, a BMP inhibitor and a sonic hedgehog signaling inhibitor; and

(ii) culturing the cells of step (i) in DMEM high glucose medium supplemented with a BMP inhibitor and a TGF-β

receptor I kinase inhibitor.

22. The method of claim 21, wherein the BMP inhibitor is noggin.

23. The method of claim 21, wherein the sonic hedgehog signaling inhibitor is cyclopamine-KAAD.

24. The method of claim 21, wherein the TGF-β

receptor I kinase inhibitor is Alk5 inhibitor II.

25. The method of claim 20, wherein the medium of step (d) further comprises betacellulin and a TGF-β

receptor I kinase inhibitor.

26. The method of claim 25, wherein the TGF-β

receptor I kinase inhibitor is Alk5 inhibitor II.

27. The method of claim 20, wherein the pancreatic endocrine precursor cells are transplanted into the renal subcapsular space, omentum, peritoneum, or subserosal space.

28. The method of claim 20, wherein the insulin expressing cells are in a biocompatible degradable polymeric support, a porous non-degradable device or encapsulated when transplanted.

29. The method of claim 28, wherein the cells are encapsulated.

30. The method of claim 29, wherein the encapsulated cells are transplanted subcutaneously.

34. The method of claim 21, wherein the insulin expressing cells are in a biocompatible degradable polymeric support, a porous non-degradable device or encapsulated when transplanted.

35. The method of claim 34, wherein the cells are encapsulated.

36. The method of claim 35, wherein the encapsulated cells are transplanted subcutaneously.

37. The method of claim 20 or 31, wherein the DMEM-high glucose medium comprises a TGF-β

receptor I kinase inhibitor.

39. The method of claim 20, wherein the transplanted pancreatic endocrine precursor cells of step (c) further differentiate in vivo into insulin producing cells.

31. A method for lowering blood glucose levels in a mammal, comprising the steps of:

(a) obtaining a population of definitive endoderm cells,

(b) differentiating a population of definitive endoderm cells into a population of pancreatic endoderm cells,

(c) differentiating the pancreatic endoderm cells of step (b) in a DMEM-high glucose medium comprising an exogenous retinoid to obtain a population of pancreatic endocrine precursor cells expressing insulin, NKX6.1 and PDX1, but not expressing CDX2, wherein the pancreatic endocrine precursor cells have increased expression of NKX6.1, PFT1a and NGN-3 as compared to pancreatic endocrine cells obtained from pancreatic endoderm cells differentiated in DMEM-low glucose, CMRL and DM-F12,

(d) differentiating the pancreatic endocrine precursor cells of step (c) in a DMEM-high glucose medium to obtain a population of cells expressing insulin; and

(e) transplanting the population of insulin expressing cells of step (d) into the liver, natural pancreas, renal subcapsular space, omentum, peritoneum, subserosal space, intestine, or a subcutaneous pocket of the mammal, wherein the pancreatic endocrine precursor cells express insulin, lower the blood glucose levels in the mammal and are protected from host immune response when transplanted.

32. The method of claim 31, wherein the medium of step (d) further comprises betacellulin and a TGF-β

receptor I kinase inhibitor.

33. The method of claim 32, wherein the TGF-β

receptor I kinase inhibitor is Alk5 inhibitor II.